Effect and safety of sivelestat on acute severe pancreatitis with systemic inflammatory response syndrome: A retrospective study

Abstract

Abstract Purpose To explore the efficacy and safety of sivelestat (SV) in the treatment of severe acute pancreatitis (SAP) with systemic inflammatory response syndrome (SIRS). Methods A total of 71 SAP patients diagnosed and treated in the Emergency Intensive Care Unit of the First Affiliated Hospital of Zhengzhou University from January 2021 to June 2023 were selected. The changes of disease outcome, hospital stays and mortality were compared between the two groups. Results A total of 71 patients were recruited to control group (n = 42) or SV group (n = 29) according to whether SV was applied or not. There was no significant difference in baseline data at admission between the two groups. After 1 week of treatment, all the indexes in both groups improved. The duration of ventilator use in SV group was shorter than that in control group (p = 0.0302), but there was no significant difference in hospital stays and mortality between the two groups. Conclusion SV had a good safety in the treatment of SAP combined with SIRS, and could shorten the ventilator use time of patients with respiratory failure, but could not reduce the hospital stays and mortality.